All About IVIG (Intravenous Immunoglobulin)
HealthTree University: Know Your Therapy
Intravenous Immunoglobulin (IVIG) is a product made from antibodies collected from the plasma of healthy individuals. The antibodies are proteins that help fight infections and are part of the blood's plasma. The plasma is collected from 10,000 to 50,000 individuals with normal immune systems and is then given intravenously through a vein to help strengthen the recipient's immune system and fight infections. IVIG is used in multiple conditions, including immune deficiencies, autoimmune diseases, and some neurological conditions. IVIG can be administered intravenously, subcutaneously, or intramuscularly. For myeloma patients, IVIG is usually administered every three to four weeks at a dose of 0.4 grams per kilogram. The frequency of IVIG administration may vary based on the individual's steady state levels of immunoglobulin. Learn more in depth in the video below!
You can watch the whole Know Your Therapy course on HealthTree University. With a HealthTree University account you can track your myeloma progress, make notes, take quizzes to test comprehension, and bookmark favorite lessons.
12.22 All about IVIG (Intravenous Immunoglobulin)
We’d like to thank our faculty who donated their time in creating these videos, including:
- Urvi Shah, MD
Want more?
We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!
- Myeloma Basics Part 1
- Myeloma Basics Part 2
- Myeloma Basics Part 3
- Myeloma Care Basics
- Building Your Healthcare Team
- Becoming an Empowered Patient
- Starting Myeloma Treatment
- Know Your Therapy
- Know Your Labs: Blood and Urine Testing in Myeloma
- Autologous Stem Cell Transplant (ASCT)
- Precursor Conditions
- Relapsed and Refractory MM Treatment
- Classes of Drugs
- Immunotherapy
- Myeloma Bone Disease
- Imaging in Myeloma
- MRD Testing
- Basic Genetics and Cancer Biology
- Myeloma Genetics
- Types of Genetic Testing in Myeloma
- Specific Myeloma Genetics Mutations and Risk
- Precision Medicine
- Financial Advice for Myeloma Patients and Their Families
- Geriatric Care and Myeloma
- Myeloma Kidney Disease
- Amyloidosis
- Myeloma Basics (Spanish)
- COVID-19 and Multiple Myeloma
- Complementary and Integrated Therapy
- Allogeneic Stem Cell Transplant
- Survivorship
- Clinical Trials
- Understanding Basic Blood tests
- Myeloma Vaccines
HealthTree University: Know Your Therapy
Intravenous Immunoglobulin (IVIG) is a product made from antibodies collected from the plasma of healthy individuals. The antibodies are proteins that help fight infections and are part of the blood's plasma. The plasma is collected from 10,000 to 50,000 individuals with normal immune systems and is then given intravenously through a vein to help strengthen the recipient's immune system and fight infections. IVIG is used in multiple conditions, including immune deficiencies, autoimmune diseases, and some neurological conditions. IVIG can be administered intravenously, subcutaneously, or intramuscularly. For myeloma patients, IVIG is usually administered every three to four weeks at a dose of 0.4 grams per kilogram. The frequency of IVIG administration may vary based on the individual's steady state levels of immunoglobulin. Learn more in depth in the video below!
You can watch the whole Know Your Therapy course on HealthTree University. With a HealthTree University account you can track your myeloma progress, make notes, take quizzes to test comprehension, and bookmark favorite lessons.
12.22 All about IVIG (Intravenous Immunoglobulin)
We’d like to thank our faculty who donated their time in creating these videos, including:
- Urvi Shah, MD
Want more?
We have over 500 HealthTree University videos online at HealthTree University! Learn the basics (and the not-so-basics) of myeloma from some of the top myeloma doctors in the world!
- Myeloma Basics Part 1
- Myeloma Basics Part 2
- Myeloma Basics Part 3
- Myeloma Care Basics
- Building Your Healthcare Team
- Becoming an Empowered Patient
- Starting Myeloma Treatment
- Know Your Therapy
- Know Your Labs: Blood and Urine Testing in Myeloma
- Autologous Stem Cell Transplant (ASCT)
- Precursor Conditions
- Relapsed and Refractory MM Treatment
- Classes of Drugs
- Immunotherapy
- Myeloma Bone Disease
- Imaging in Myeloma
- MRD Testing
- Basic Genetics and Cancer Biology
- Myeloma Genetics
- Types of Genetic Testing in Myeloma
- Specific Myeloma Genetics Mutations and Risk
- Precision Medicine
- Financial Advice for Myeloma Patients and Their Families
- Geriatric Care and Myeloma
- Myeloma Kidney Disease
- Amyloidosis
- Myeloma Basics (Spanish)
- COVID-19 and Multiple Myeloma
- Complementary and Integrated Therapy
- Allogeneic Stem Cell Transplant
- Survivorship
- Clinical Trials
- Understanding Basic Blood tests
- Myeloma Vaccines
about the author
Cynthia Chmielewski
Cynthia (Cindy) Chmielewski is a professional educator and myeloma advocate. As a former teacher, she now teaches myeloma patients how to advocate for themselves as the Director of HealthTree University. You can follow her on Twitter @myelomateacher
More on Core Education
Trending Articles
Upcoming Events
Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox
Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.